Strive

Strive, operating at strivemath.com, is a telehealth platform that has surfaced in AI-generated answers about compounded GLP-1 medications. Its current AI visibility is limited but measurable: WellRank places it at rank 14 in the Compounded GLP-1s category with 8% visibility, and the single mention in the WellRank corpus carries a neutral tone, suggesting early-stage recognition rather than established authority in the space.

Strive appears to operate as a telehealth or digital health service with a presence in the compounded GLP-1 market, connecting patients with access to compounded semaglutide or related weight-loss medications. Its founding date and headquarters are not publicly disclosed. The business model is not fully detailed in public sources, but its domain name and category placement suggest a direct-to-consumer or clinician-mediated telehealth approach.

• Access to compounded GLP-1 medications (such as semaglutide-based formulations)
• Online telehealth consultation for weight management
• Prescription fulfillment through compounding pharmacy partnerships
• Digital patient intake and health assessment workflow

Strive appears to target adults seeking weight loss support, particularly those interested in compounded GLP-1 therapies as an alternative to branded medications. Geographic coverage is not publicly confirmed, though the compounded GLP-1 market it operates in is primarily US-focused, a context well documented by sources such as GoodRx on compounded GLP-1 availability and Scientific American's coverage of FDA oversight.

• A cost-conscious adult who cannot afford branded semaglutide and is exploring compounded alternatives through online telehealth platforms.
• A patient already familiar with GLP-1 therapy who wants a streamlined digital refill or consultation experience.
• A weight-management-motivated individual who prefers remote care over in-person clinical visits.
• A healthcare-aware consumer researching multiple compounded GLP-1 providers before committing to one service.

Funding stage, investor backing, valuation, and company scale are not publicly disclosed.

Strive has emerged organically in AI answers about compounded GLP-1s at a time when the regulatory environment for these medications is actively shifting, as the FDA has moved to restrict certain compounded semaglutide products. The company has not yet been formally profiled by major health or business media, and no specific product launches or partnership announcements are widely documented in public sources.

The WellRank corpus contains one AI mention of Strive, which is neutral in tone, with no positive or cautious signals recorded. This pattern suggests AI engines are beginning to surface the brand in relevant queries but have not yet formed a strong evaluative stance, which is consistent with a brand that lacks substantial independent editorial coverage or user review volume at this stage.

Pricing is not publicly published in widely available sources. As with most compounded GLP-1 telehealth providers, costs likely vary based on medication formulation, dosage, and consultation fees.